Physician profile
John B Rasor
NPI 1124089800
$698.65
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $128.45 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $89.17 | 2019 | |
| Amgen INC. | $65.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.61 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $49.94 | 2019 | |
| Abbvie INC. | $48.13 | 2019 | |
| Indivior INC. | $46.31 | 2019 | |
| Sanofi-Aventis U.S. LLC | $41.22 | 2019 | |
| Lilly USA, LLC | $34.27 | 2019 | |
| Pfizer INC. | $28.98 | 2019 | |
| Bausch Health US, LLC | $27.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.69 | 2019 | |
| Amarin Pharma, INC. | $16.75 | 2019 | |
| Merck Sharp & Dohme LLC | $14.04 | 2019 | |
| Phadia US INC. | $12.82 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $10.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rasor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.